Harbor Capital Advisors Inc. Boosts Holdings in Certara, Inc. (NASDAQ:CERT)

Harbor Capital Advisors Inc. raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 16.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,294 shares of the company’s stock after purchasing an additional 2,834 shares during the period. Harbor Capital Advisors Inc.’s holdings in Certara were worth $201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CERT. Versant Capital Management Inc lifted its holdings in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in Certara during the fourth quarter valued at $47,000. Finally, ANTIPODES PARTNERS Ltd lifted its holdings in Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after purchasing an additional 3,656 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. KeyCorp raised their price target on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Barclays raised shares of Certara from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Robert W. Baird raised their price target on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Finally, Stephens reissued an “overweight” rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.67.

Certara Price Performance

Certara stock opened at $11.01 on Monday. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $16.93. The stock has a market cap of $1.79 billion, a P/E ratio of -55.05, a PEG ratio of 9.29 and a beta of 1.44. The company has a 50-day moving average price of $12.22 and a 200 day moving average price of $11.88. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same quarter in the prior year, the company posted $0.10 EPS. The company’s quarterly revenue was up 9.7% on a year-over-year basis. Sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.